Sandoz v. Amgen: Biosimilars arrive at the Supreme Court By Michael Weil Intellectual Property Law Newsletter Related Practices: Intellectual Property June 2017 Senior associate Michael Weil co-authored "Sandoz v. Amgen: Biosimilars arrive at the Supreme Court" in the June 2017 Intellectual Property Law Newsletter. To read full article click here. Related Content June 9, 2022 The Legal 500 Recommends Kelley Drye Attorneys and Practice Groups for 2022 List The 2022 edition of US Legal 500, which ranks l... June 29, 2022 AI and U.S. Patent Laws: Forward-Looking Strategies for Startups Launching a startup requires innovative ideas... June 1, 2022 Kelley Drye Adds Leading Technology Attorney Scott Doyle Kelley Drye & Warren LLP announced that pro... May 18, 2017 A Hypothetical Case Study: Leveraging a Portfolio of Various IP Rights to Enjoin Sales of Counterfeit Products Partner Scott Doyle presented "A Hypotheti... June 23, 2015 Brulotte Rule Upheld Despite Suspect Economic Rationale Partner Scott Doyle co-authored &ldqu... July 17, 2015 Supreme Court’s Commil Decision Offers Both Good and Bad News for Patent Holders Partner Scott Doyle co-authored &ldqu... September 2015 Squaring up to NPEs Partner Scott Doyle co-authored &ldqu... September 2015 Strategies for a Successful Petition for Inter Partes Review Partner Scott Doyle co-authored &ldqu... November 20, 2015 Lexmark Is Much Ado About Nothing – For Now Partner Scott Doyle co-authored &ldqu... May 2016 The Rise of the Super Patent Partner Scott Doyle co-authored &ldqu...